{"id":1075,"date":"2022-03-31T10:56:37","date_gmt":"2022-03-31T08:56:37","guid":{"rendered":"https:\/\/lensounds.com\/2022\/03\/31\/ionetix-et-atonco-signent-un-accord-de-partenariat-pour-lutter-contre-le-cancer-de-la-vessie\/"},"modified":"2026-03-06T18:30:43","modified_gmt":"2026-03-06T17:30:43","slug":"ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer","status":"publish","type":"post","link":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/","title":{"rendered":"IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER"},"content":{"rendered":"\n<p><strong>Atonco<\/strong> (Nantes-Saint Herblain, France) and <strong>Ionetix<\/strong> (Lansing, MI, USA) have signed a partnership agreement to ensure GMP manufacturing and supply of the radiopharmaceutical product required for the success of Atonco&#8217;s clinical studies and commercialization in the United States.<\/p>\n\n\n\n<p>Atonco, a clinical-stage radiopharmaceutical company, aims to demonstrate through its clinical research program the relevance of a groundbreaking therapeutic treatment \u2014 alpha immunotherapy \u2014 targeting non-muscle-invasive bladder cancer.<\/p>\n\n\n\n<p><strong>IONETIX Corporation<\/strong> operates a GMP-compliant North American manufacturing and supply chain for alpha-emitting radiopharmaceuticals. Through this agreement, Ionetix will make available its astatine-211 radioisotope production capabilities and its network of radiopharmacies to manufacture patient doses in accordance with Good Manufacturing Practice (GMP).<\/p>\n\n\n\n<p>The agreement covers the supply of the astatine-211 radioisotope, GMP manufacturing of injectable doses, and specifies the terms of the FDA agent agreement signed in August 2021.<\/p>\n\n\n\n<p>IONETIX is pioneering the first commercial-scale supply of astatine-211 in North America from its cyclotron production facility in Lansing, MI.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>David Eve, Vice President of Medical Affairs:<\/strong> &#8220;We are very excited about the partnership with Atonco, which will allow us to actively collaborate in its clinical development program and commercialization in the United States, subject to approval of Atonco&#8217;s drug candidates.&#8221;<\/p><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Sylvain Fanier, Chairman of Atonco:<\/strong> &#8220;This partnership agreement is a key milestone in Atonco&#8217;s development. We are convinced that Ionetix is the most reliable and advanced partner to ensure optimal supply for our clinical development and commercialization in North America. Thanks to their expertise and experience in radiopharmaceutical manufacturing and FDA discussions, Ionetix will greatly contribute to our shared success in offering bladder cancer patients a highly promising therapeutic alternative.&#8221;<\/p><\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">About IONETIX<\/h3>\n\n\n\n<p>IONETIX leverages its growing network of radiopharmaceutical manufacturing sites to support the development and commercialization of targeted alpha therapy (TAT). TAT is an emerging cancer treatment using alpha-emitting radionuclides that delivers high-energy alpha particles to cancer cells and the tumor microenvironment to treat cancer while sparing healthy tissues.<\/p>\n\n\n\n<p>For more information, visit <a href=\"https:\/\/www.ionetix.com\/\">www.ionetix.com<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">About ATONCO<\/h3>\n\n\n\n<p>ATONCO is a French private company developing targeted molecular radiation products for oncological applications. Originating from the world-class nuclear medicine centre in Nantes, ATONCO and its partners are committed to the clinical use of alpha-emitting radionuclides, particularly astatine-211 (211At).<\/p>\n\n\n\n<p>For more information, visit <a href=\"http:\/\/www.atonco-pharma.com\/\">www.atonco-pharma.com<\/a><\/p>\n\n\n\n<p><a href=\"\/wp-content\/uploads\/2025\/11\/2022-03-31_ATONCO_IONETIX_Partnership.pdf\">PDF Version >><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Atonco (Nantes-Saint Herblain, France) and Ionetix (Lansing, MI, USA) have signed a partnership agreement to ensure GMP manufacturing and supply of the radiopharmaceutical product required for the success of Atonco&#8217;s clinical studies and commercialization in the United States. Atonco, a clinical-stage radiopharmaceutical company, aims to demonstrate through its clinical research program the relevance of a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1076,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48],"tags":[],"class_list":["post-1075","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-atonco-press-releases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ionetix &amp; Atonco Sign Partnership for Alpha Radiopharmaceutical Manufacturing<\/title>\n<meta name=\"description\" content=\"Atonco and Ionetix partner for GMP manufacturing and North American supply of astatine-211 radiopharmaceuticals for bladder cancer studies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ionetix &amp; Atonco Sign Partnership for Alpha Radiopharmaceutical Manufacturing\" \/>\n<meta property=\"og:description\" content=\"Atonco and Ionetix partner for GMP manufacturing and North American supply of astatine-211 radiopharmaceuticals for bladder cancer studies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-31T08:56:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-06T17:30:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2022\/03\/microbe-610.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin27\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin27\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/\"},\"author\":{\"name\":\"admin27\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\"},\"headline\":\"IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER\",\"datePublished\":\"2022-03-31T08:56:37+00:00\",\"dateModified\":\"2026-03-06T17:30:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/\"},\"wordCount\":383,\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/microbe-610.jpg\",\"articleSection\":[\"Atonco press release\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/\",\"name\":\"Ionetix & Atonco Sign Partnership for Alpha Radiopharmaceutical Manufacturing\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/microbe-610.jpg\",\"datePublished\":\"2022-03-31T08:56:37+00:00\",\"dateModified\":\"2026-03-06T17:30:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\"},\"description\":\"Atonco and Ionetix partner for GMP manufacturing and North American supply of astatine-211 radiopharmaceuticals for bladder cancer studies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/microbe-610.jpg\",\"contentUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/microbe-610.jpg\",\"width\":640,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2022\\\/03\\\/31\\\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\",\"name\":\"admin27\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"caption\":\"admin27\"},\"sameAs\":[\"https:\\\/\\\/pulsheart-medical.com\"],\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/author\\\/admin27\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ionetix & Atonco Sign Partnership for Alpha Radiopharmaceutical Manufacturing","description":"Atonco and Ionetix partner for GMP manufacturing and North American supply of astatine-211 radiopharmaceuticals for bladder cancer studies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Ionetix & Atonco Sign Partnership for Alpha Radiopharmaceutical Manufacturing","og_description":"Atonco and Ionetix partner for GMP manufacturing and North American supply of astatine-211 radiopharmaceuticals for bladder cancer studies.","og_url":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/","og_site_name":"Atonco","article_published_time":"2022-03-31T08:56:37+00:00","article_modified_time":"2026-03-06T17:30:43+00:00","og_image":[{"width":640,"height":360,"url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2022\/03\/microbe-610.jpg","type":"image\/jpeg"}],"author":"admin27","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin27","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/#article","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/"},"author":{"name":"admin27","@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5"},"headline":"IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER","datePublished":"2022-03-31T08:56:37+00:00","dateModified":"2026-03-06T17:30:43+00:00","mainEntityOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/"},"wordCount":383,"image":{"@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2022\/03\/microbe-610.jpg","articleSection":["Atonco press release"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/","url":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/","name":"Ionetix & Atonco Sign Partnership for Alpha Radiopharmaceutical Manufacturing","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/#primaryimage"},"image":{"@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2022\/03\/microbe-610.jpg","datePublished":"2022-03-31T08:56:37+00:00","dateModified":"2026-03-06T17:30:43+00:00","author":{"@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5"},"description":"Atonco and Ionetix partner for GMP manufacturing and North American supply of astatine-211 radiopharmaceuticals for bladder cancer studies.","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/#primaryimage","url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2022\/03\/microbe-610.jpg","contentUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2022\/03\/microbe-610.jpg","width":640,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/2022\/03\/31\/ionetix-atonco-sign-partnership-agreement-fight-bladder-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5","name":"admin27","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","caption":"admin27"},"sameAs":["https:\/\/pulsheart-medical.com"],"url":"https:\/\/atonco-pharma.com\/en\/author\/admin27\/"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/comments?post=1075"}],"version-history":[{"count":16,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1075\/revisions"}],"predecessor-version":[{"id":1122,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1075\/revisions\/1122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media\/1076"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/categories?post=1075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/tags?post=1075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}